Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) traded at $35.25 at last check on Monday, Sep 14, making an upward move of 11.2% on its previous day’s price.
Looking at the stock we see that its previous close was $31.7 and the beta (5Y monthly) reads 0.98. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, IOVA has a high of $41.49 and a low of $17.67. The company’s stock has gained about 22.99% over that past 30 days.
There have been no upward or downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the IOVA stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 12 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Iovance Biotherapeutics, Inc. (IOVA) stock as a Hold, while 11 rate it as a Buy. 1 analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the IOVA stock currently stands at 0, and the current price level is 15.8% off its SMA20 and 18.09% from its 50-day simple moving average. The RSI (14) is pointing at 66.69 while the volatility over the past week is 5.98% and drops to 5.37% over the past one month. The beta value is 0.98, while the average true range (ATR) is currently pointing at 1.78. The average price target for the stock over the next 12 months is $48.18, with the estimates having a low of $38 and a high of $61. These price ends are 7.8% and +73.05% off the current price level respectively, although investors could be excited at the prospect of a +36.17% if the IOVA share price touches on the median price of $48.
Let’s briefly compare Iovance (IOVA) stock to its peers. We find that today’s price change of +11.2% and +64.41% over the past 12 months for IOVA betters that of Amgen Inc (AMGN), which has seen its stock price rise 1.46% in the latest trading session and is +26.23% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.2% today, and is +20.78% up over the past year, while Gilead Sciences Inc (GILD) is also up 11.2% yet its price remains in the green at 64.41% over the same period. Amgen has a P/E ratio of 20.16 compared to Iovance’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.27% and 1.18%, respectively, in early deals.